CL2008000981A1 - Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu - Google Patents

Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu

Info

Publication number
CL2008000981A1
CL2008000981A1 CL200800981A CL2008000981A CL2008000981A1 CL 2008000981 A1 CL2008000981 A1 CL 2008000981A1 CL 200800981 A CL200800981 A CL 200800981A CL 2008000981 A CL2008000981 A CL 2008000981A CL 2008000981 A1 CL2008000981 A1 CL 2008000981A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
aterosclerotic
carboxamida
imidazolidin
disorders
Prior art date
Application number
CL200800981A
Other languages
English (en)
Inventor
Gerhard Zoller
Stefan Petry
Gunter; Muller
Norbert. Tennagles
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2008000981A1 publication Critical patent/CL2008000981A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/76Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
CL200800981A 2007-04-05 2008-04-04 Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu CL2008000981A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07007161 2007-04-05

Publications (1)

Publication Number Publication Date
CL2008000981A1 true CL2008000981A1 (es) 2008-10-10

Family

ID=38169713

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800981A CL2008000981A1 (es) 2007-04-05 2008-04-04 Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu

Country Status (20)

Country Link
US (1) US8735437B2 (es)
EP (1) EP2144885B1 (es)
JP (1) JP2010523503A (es)
KR (1) KR20090126293A (es)
CN (1) CN101646655A (es)
AR (1) AR065932A1 (es)
AU (1) AU2008235066A1 (es)
BR (1) BRPI0809693A2 (es)
CA (1) CA2682875A1 (es)
CL (1) CL2008000981A1 (es)
CO (1) CO6220934A2 (es)
IL (1) IL201255A0 (es)
MA (1) MA31296B1 (es)
MX (1) MX2009010485A (es)
NZ (1) NZ580127A (es)
RU (1) RU2009140761A (es)
TW (1) TW200904804A (es)
UY (1) UY31001A1 (es)
WO (1) WO2008122352A1 (es)
ZA (1) ZA200906211B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9493412B2 (en) 2011-09-27 2016-11-15 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
EP2760829B1 (en) * 2011-09-27 2016-05-18 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9249096B2 (en) 2011-09-27 2016-02-02 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US8933235B2 (en) 2011-09-30 2015-01-13 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
US9394260B2 (en) 2012-04-03 2016-07-19 Bristol-Myers Squibb Company Pyrimidinone carboxamide inhibitors of endothelial lipase
WO2013151877A1 (en) * 2012-04-03 2013-10-10 Bristol-Myers Squibb Company Pyrimidinedione carboxamide inhibitors of endothelial lipase
AR102942A1 (es) 2014-12-11 2017-04-05 Bayer Cropscience Ag Derivados de arilsulfuro y arilsulfóxido de cinco miembros c-n-conectados, como plaguicidas

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03227976A (ja) * 1990-02-01 1991-10-08 Otsuka Chem Co Ltd イミダゾリジン―2―オン誘導体
JP3227976B2 (ja) 1993-02-26 2001-11-12 松下電器産業株式会社 光学的情報記録部材、記録再生方法、及び記録再生装置
JP3947283B2 (ja) 1997-11-19 2007-07-18 株式会社堀場製作所 イプロジオン及びその代謝物のハプテン化合物、抗体及び測定方法
DE60100811T2 (de) * 2000-05-18 2004-07-01 Neurocrine Biosciences, Inc., San Diego Crf rezeptor-antagonisten und darauf bezogene methoden
DE602004023062D1 (en) 2003-03-31 2009-10-22 Lilly Co Eli 3-oxo-1,3-dihydro-indazol-2-carbonsäureamid derivate als phospholipase inhibitoren
US7595403B2 (en) 2003-04-01 2009-09-29 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
EP1613608A1 (en) 2003-04-01 2006-01-11 Eli Lilly And Company Phospholipase inhibitors
US20090253908A1 (en) * 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
DE102005018389A1 (de) 2005-04-20 2006-10-26 Sanofi-Aventis Deutschland Gmbh Azolderivate als Inhibitoren von Lipasen und Phospholipasen

Also Published As

Publication number Publication date
IL201255A0 (en) 2010-05-31
CA2682875A1 (en) 2008-10-16
TW200904804A (en) 2009-02-01
BRPI0809693A2 (pt) 2014-10-07
CN101646655A (zh) 2010-02-10
UY31001A1 (es) 2008-11-28
EP2144885B1 (de) 2016-06-29
MA31296B1 (fr) 2010-04-01
KR20090126293A (ko) 2009-12-08
US20100105719A1 (en) 2010-04-29
NZ580127A (en) 2011-03-31
EP2144885A1 (de) 2010-01-20
AU2008235066A1 (en) 2008-10-16
CO6220934A2 (es) 2010-11-19
AR065932A1 (es) 2009-07-08
WO2008122352A1 (de) 2008-10-16
JP2010523503A (ja) 2010-07-15
ZA200906211B (en) 2010-05-26
US8735437B2 (en) 2014-05-27
MX2009010485A (es) 2009-10-19
RU2009140761A (ru) 2011-05-10

Similar Documents

Publication Publication Date Title
CL2008000981A1 (es) Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu
CL2007001882A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
CL2008000531A1 (es) Compuestos derivados de heterociclos, inhibidores de la aspartilproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades cardiovasculares, cognitivas y neurodegenerativas tales como la enfermeda
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
CL2007001881A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
CL2008003407A1 (es) Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007002910A1 (es) Composicion farmaceutica que comprende compuestos derivados de anillos monociclicos, biciclicos o triciclicos, inhibidores de amidohidrolasa de acidos grasos; complejo que comprende al compuesto; y uso en el tratamiento de enfermedades tales como dol
SMT201600055B (it) Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
BRPI0917444A2 (pt) composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
BRPI0818799A2 (pt) Composições para o tratamento da doença de parkinson
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
CL2013001654A1 (es) Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
EP2107909A4 (en) PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF HEPATIC DISORDERS
CL2007003879A1 (es) Compuestos derivados de aril-carboxamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alzheimer, epilepsia y parkinson.
CL2007002733A1 (es) Compuestos derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas; procedimiento de obtencion de los compuestos; composicion farmaceutica; y uso para el tratamiento y prevencion de enfermedades neurodegenerativas, osteoporosis y cancer.
ES2525801T8 (es) Composiciones y métodos para la prevención y el tratamiento de enfermedades autoinmunes
CL2013002341A1 (es) Compuestos derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4 d]pirimidin-4-ona, inhibidores de pde9a; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o afección relacionado con deterioro cognitivo, enfermedad de alzheimer, demencia vascular, entre otros
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
CL2007001042A1 (es) Compuestos derivados de tioxantina; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de desordenes neuroinflamatorios como esclerosis multiple, parkinson, en desordenes ateroscleroticos, cardio- y cerebrovascular, des
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.